Supported Interventions
Each compound is given in the diet at the following levels (part per million -ppm- which is defined as milligrams of agent per kilogram of food). All testing is Stage I unless otherwise indicated.
Compound | Cohort | Concentration in Food | Age at Treatment Initiation | Increase in Median (Med) and Maximum (Max) Lifespan |
---|---|---|---|---|
4-OH-a-phenyl-N-tert-butyl nitrone (4-OH-PBN) | 2004 | 315 ppm | 4 mo | none |
aspirin (Asp) | 2004 | 20 ppm | 4 mo | Male (Med) |
nitroflurbiprofen (NFP) | 2004 | 200 ppm | 4 mo | none |
nordihydroguaiaretic acid (NDGA) | 2004 | 2500 ppm | 9 mo | Male (Med) |
caffeic acid phenethyl ester (CAPE) | 2005 | 30 ppm | 4 mo | none |
caffeic acid phenethyl ester (CAPE) | 2005 | 300 ppm | 4 mo | none |
enalapril (Enal) | 2005 | 120 ppm | 4 mo | none |
rapamycin (Rapa) | 2005 | 14 ppm | 20 mo | Male (Med, Max) & Female (Med, Max) |
rapamycin (Rapa) | 2006 | 14 ppm | 9 mo | Male (Med, Max) & Female (Med, Max) |
resveratrol (Res) | 2006 | 300 ppm | 12 mo | none |
resveratrol (Res) | 2006 | 1200 ppm | 12 mo | none |
simvastatin (Sim) | 2006 | 12 ppm | 10 mo | none |
simvastatin (Sim) | 2006 | 120 ppm | 10 mo | none |
curcumin (Cur) | 2007 | 2000 ppm | 4 mo | none |
green tea extract (GTE) | 2007 | 2000 ppm | 4 mo | none |
medium-chain triglyceride oil (MCTO) | 2007 | 60,000 ppm | 4 mo | none |
oxaloacetic acid (OAA) | 2007 | 2200 ppm | 4 mo | none |
resveratrol (Res) | 2007 | 300 ppm | 4 mo | none |
17-a-estradiol (17aE2) | 2009 | 4.8 ppm | 10 mo | Male (Med) |
acarbose (ACA) | 2009 | 1000 ppm | 4 mo | Male (Med, Max) & Female (Med, Max) |
methylene blue (MB) | 2009 | 28 ppm | 4 mo | none |
rapamycin (Rapa) - Stage II | 2009 | 4.7 ppm | 9 mo | Female (Med, Max) |
rapamycin (Rapa) - Stage II | 2009 | 14 ppm | 9 mo | Male (Med, Max) & Female (Med, Max) |
rapamycin (Rapa) - Stage II | 2009 | 42 ppm | 9 mo | Male (Med, Max) & Female (Med, Max) |
fish oil (FO) | 2010 | 15,000 ppm | 9 mo | none |
fish oil (FO) | 2010 | 50,000 ppm | 9 mo | none |
nordihydroguaiaretic acid (NDGA) - Male only, Stage II | 2010 | 800 ppm | 6 mo | Male (Med) |
nordihydroguaiaretic acid (NDGA) - Male only, Stage II | 2010 | 2500 ppm | 6 mo | Male (Med) |
nordihydroguaiaretic acid (NDGA) - Stage II | 2010 | 5000 ppm | 6 mo | Male (Med) |
17-a-estradiol (17aE2) | 2011 | 14 ppm | 10 mo | Male (Med, Max) |
metformin (Met) | 2011 | 1000 ppm | 9 mo | none |
metformin and rapamycin (MetRapa) | 2011 | Met:1000 ppm and Rapa:14 ppm | 9 mo | Male (Med, Max) & Female (Med, Max) |
Protandim (Prot) | 2011 | 600 ppm then 1200 ppm | 10 mo then 17 mo | Male (Med) |
ursodeoxycholic acid (UDCA) | 2011 | 5000 ppm | 5 mo | none |
2-(2-Hydroxyphenyl)benzoxazole (HBX) | 2012 | 1 ppm | 15 mo | none |
acarbose (ACA) | 2012 | 1000 ppm | 16 mo | Male (Med, Max) & Female (Max) |
INT-767 FXR/TGR5 agonist (INT-767) | 2012 | 180 ppm | 10 mo | none |
acarbose (ACA) - Stage II | 2013 | 400 ppm | 8 mo | Male (Med, Max) |
acarbose (ACA) - Stage II | 2013 | 1000 ppm | 8 mo | Male (Med, Max) & Female (Med, Max) |
acarbose (ACA) - Stage II | 2013 | 2500 ppm | 8 mo | Male (Med, Max) & Female (Med) |
ursolic acid (UA) | 2013 | 2000 ppm | 10 mo | none |
aspirin (Asp) | 2014 | 60 ppm | 11 mo | none |
aspirin (Asp) | 2014 | 200 ppm | 11 mo | none |
glycine (Gly) | 2014 | 80,000 ppm | 9 mo | Male (Med, Max) & Female (Med) |
inulin (Inu) | 2014 | 600 ppm | 11 mo | none |
TM5441 (TM5441) | 2014 | 60 ppm | 11 mo | none |
17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride (DMAG) | 2015 | 30 ppm | 6 mo | none |
b-guanidinopropionic acid (bGPA) | 2015 | 3300 ppm | 6 mo | none |
minocycline (Min) | 2015 | 300 ppm | 6 mo | none |
MitoQ (MitoQ) | 2015 | 100 ppm | 7 mo | none |
rapamycin (Rapa) - Stage II | 2015 | 42 ppm | 20 mo (stop at 23) | Male (Med, Max) |
rapamycin (Rapa) - Intermittent, Stage II | 2015 | 42 ppm (every other month) | 20 mo | Male (Med, Max) & Female (Med, Max) |
rapamycin (Rapa) - Stage II | 2015 | 42 ppm | 20 mo | Male (Med, Max) & Female (Med, Max) |
17-a-estradiol (17aE2) - Stage II | 2016 | 14.4 ppm | 16 or 20 mo | Male (Med) |
3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one (MIF098) | 2016 | 240 ppm | 8 mo | none |
canagliflozin (Cana) | 2016 | 180 ppm | 7 mo | Male (Med, Max) |
candesartan cilexetil (CC) | 2016 | 30 ppm | 7 mo | none |
geranylgeranyl acetone (GGA) | 2016 | 600 ppm | 9 mo | none |
nicotinamide riboside (NR) | 2016 | 1000 ppm | 8 mo | none |
Hydrogen Sulfide prodrug SG1002 | 2016 | 240 ppm | 19 mo | none |
1,3-butanediol (BD) | 2017 | 100,000 ppm | 6 mo | none |
Captopril (Capt) | 2017 | 180 ppm | 5 mo | Female (Med); Male Results Indeterminant |
L-Leucine (Leu) | 2017 | 40,000 ppm | 5 mo | none |
PB125 | 2017 | 100 ppm | 5 mo | none |
Sulindac (Sul) | 2017 | 5 ppm | 5 mo | none |
Syringaresinol (Syr) | 2017 | 300 ppm | 5 mo | none |
Rapamycin + Acarbose (RaAc) - Stage II | 2017 | Ra: 14.7 ppm and Ac: 1000 ppm | 9 mo or 16 mo | Male (Med, Max) & Female (Med, Max) |
Fisetin (Fis) | 2018 | 600 ppm | 20 mo | none |
Fisetin (Fis) - Cycling | 2018 | 600 ppm (3 days on/11 days off) | 20 mo | none |
Hydrogen Sulfide prodrug SG1002 | 2018 | 240 ppm | 18 mo | none |
Astaxanthin (Asta) | 2019 | 4000 ppm | 12 mo | In Progress |
Dimethyl Fumarate (DMF) | 2019 | 120 ppm | 9 mo or 16 mo | In Progress |
Meclizine (Mec) | 2019 | 800 ppm | 12 mo | In Progress |
Mycophenolic Acid (MPA) | 2019 | 6.7 ppm | 9 mo | In Progress |
4-Phenylbutyrate (PBA) | 2019 | 1000 ppm | 9 mo | In Progress |
Hydrogen Sulfide prodrug SG1002 | 2019 | 240 ppm | 6 mo | In Progress |
16 alpha-hydroxyestradiol | 2020 | 5 ppm | 12 mo | In Progress |
2,4-Dinitrophenol (DNP) | 2020 | 3 ppm | 6 mo | In Progress |
Hydralazine | 2020 | 30 ppm | 6 mo | In Progress |
Hydralazine | 2020 | 30 ppm | 16 mo | In Progress |
Nebivolol | 2020 | 60 ppm | 6 mo | In Progress |
Sodium Thiosulfate (STS) | 2020 | 10,000 ppm | 6 mo | In Progress |
Canagliflozin (Cana) - Stage II | 2020 | 180 ppm | 16 mo | In Progress |
alpha-ketoglutarate (AKG) | 2020 | 20,000 ppm | 18 mo | In Progress |
2BAct (2BA) | 2021 | 30 ppm | 7 mo | In Progress |
Dichloroacetate (DCA) | 2021 | 30 ppm | 7 mo | In Progress |
Epicatechin (Epi) | 2021 | 60 ppm | 7 mo | In Progress |
Forskolin (For) | 2021 | 5 ppm | 7 mo | In Progress |
Halofuginone (Hal) | 2021 | 0.6 ppm | 7 mo | In Progress |
MSDC-160 (M160) | 2021 | 300 ppm | 7 mo | In Progress |
alpha-ketoglutarate (AKG) | 2022 | 20,000 ppm | 7 mo | In Progress |
Atorvastatin + Telmisartan (AtorTel) | 2022 | Ator: 120 ppm; Tel:30 ppm | 7 mo | In Progress |
Metformin + Nicotinamide Riboside (Met + NR) | 2022 | Met: 1000 ppm; NR: 2400 ppm | 20 mo | In Progress |
Methotrexate | 2022 | 0.2 ppm | 14 mo | In Progress |
Mifepristone (Mife) | 2022 | 30 ppm | 7 mo | In Progress |
Pioglitazone (Pio) | 2022 | 100 ppm | 7 mo | In Progress |
Captopril (Capt) | 2022 | TBD | TBD | In Progress |
Meclizine (Mec) | 2022 | 2400 ppm | 16 mo | In Progress |
Meclizine (Mec) - Males only | 2022 | 800 ppm | 16 mo | In Progress |
Astaxanthin (Asta) | 2022 | 800 ppm | 11 mo | In Progress |
Astaxanthin (Asta) - Males only | 2022 | 800 ppm | 16 mo | In Progress |